Drug Profile
AFC 5278
Latest Information Update: 27 Sep 2023
Price :
$50
*
At a glance
- Originator Affectis Pharmaceuticals
- Class
- Mechanism of Action Purinergic P2X7 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Osteoporosis
Most Recent Events
- 27 Sep 2023 Discontinued - Preclinical for Osteoporosis in Germany (PO)
- 28 Oct 2020 No recent reports of development identified for preclinical development in Osteoporosis in Germany (PO)
- 16 Sep 2016 Preclinical trials in Osteoporosis in Germany (PO)